Laboratory validation of formal concept analysis of the methylation status of microarray-detected genes in primary breast cancer
Open Access
- 15 June 2017
- journal article
- research article
- Published by SAGE Publications in Tumor Biology
- Vol. 39 (6)
Abstract
Breast cancer is the leading cause of cancer-related mortality. DNA methylations play important roles in cancer development and progression. Formal concept analysis was previously utilized for data mining hypermethylated and hypomethylated genes in breast cancer molecular subtypes in illumina methylation–based microarray database, to laboratory validate their outputs; HS3ST2 (heparan sulfate d-glucosaminyl 3-O-sulfonyl transferase-2) and MUC1 (mucin-1) were retrieved. Both play important roles in progression and invasion of breast cancer. The methylation status of both genes was laboratory validated using methylation-based polymerase chain reaction in breast cancer subtypes luminal A (early stages) and luminal B (late stages) in comparison with benign conditions and normal breast to conclude their roles in tumor invasion and to validate the newly developed algorithm (formal concept analysis). Significant cancer-specific hypermethylation of HS3ST2 was detected in luminal B (chi square = 30.6, p = 0.000), while significant cancer-specific hypomethylation of MUC1 was detected in luminal B (chi square = 30.5, p = 0.001) breast cancer. The median levels of the percentage of methylated allele of both genes were significantly discriminative between luminal A and luminal B subtypes and benign and healthy control groups. Detection of MUC1 and HS3ST2 promoter methylation status appears to be useful molecular markers for assessing the progressive state of the disease and could be helpful in discriminating breast cancer molecular subtypes. These results validate the methylation-based microarray analysis, thus trust their output in the future.Keywords
This publication has 27 references indexed in Scilit:
- Applying formal concept analysis for visualizing DNA methylation status in breast cancer tumor subtypes2013
- MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approachesOncogene, 2012
- DNA methylation epigenotypes in breast cancer molecular subtypesBreast Cancer Research, 2010
- Mucins in cancer: function, prognosis and therapyNature Reviews Cancer, 2009
- DNA Methylation as a Biomarker in Breast CancerFuture Oncology, 2009
- Epigenetics: methylation‐associated repression of heparan sulfate 3‐ O ‐sulfotransferase gene expression contributes to the invasive phenotype of H‐EMC‐SS chondrosarcoma cellsThe FASEB Journal, 2009
- Shedding of Syndecan-1 by Stromal Fibroblasts Stimulates Human Breast Cancer Cell Proliferation via FGF2 ActivationJournal of Biological Chemistry, 2007
- Heparan sulphate proteoglycans fine-tune mammalian physiologyNature, 2007
- High-throughput DNA methylation profiling using universal bead arraysGenome Research, 2006
- Methylation-associated silencing of heparan sulfate D-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancersOncogene, 2003